Aratana launched a new option for managing post-operative pain at ACVS Surgery Summit
Last week, Aratana Therapeutics launched NOCITA® (bupivacaine liposome injectable suspension) to conference attendees at the 2016 American College of Veterinary Surgeons (ACVS) Surgery Summit in Seattle. In August 2016, NOCITA received FDA approval as a long-acting post-operative local analgesia following cranial cruciate ligament (CCL) surgery in dogs. It is the third therapeutic in the Aratana portfolio to be approved by the FDA this year.
NOCITA is a long-acting local anesthetic that provides up to 72 hours of pain control following CCL surgery in dogs. It works by releasing bupivacaine over time from multivesicular liposomes deposited in the tissue when administered by tissue infiltration injection during surgical closure.
ACVS attendees had the opportunity to attend Aratana-sponsored lectures, including a Friday lunch session entitled “Osteosarcoma in Dogs: New Therapeutic Advances” presented by Nicole Ehrhart, VMD, MS, DACVS, ACVS Founding Fellow, Surgical Oncology, Colorado State University, as well as a Saturday breakfast session entitled “Post-Operative Pain in Dogs: New Advances for Extended Pain Relief” presented by Duncan Lascelles, BSc, BVSc, PhD, MRCVS, CertVA, DSAS (ST), DECVS, DACVS, NC State University and Jessica Wofford, DVM, PhD, Aratana Therapeutics.
During the Saturday breakfast session, Dr. Lascelles highlighted the need for extended post-operative pain control and the benefits of making NOCITA part of a multimodal approach for pain management, while Dr. Wofford presented the safety and efficacy data for use of NOCITA for post-operative pain relief following CCL surgery in dogs.
Dr. Wofford detailed the pivotal efficacy and safety data for NOCITA, including results from a multi-center, placebo-controlled, randomized and masked field study of 182 client-owned dogs undergoing cranial cruciate ligament stabilization surgery. In this study, NOCITA-treated dogs had a statistically significant larger success rate as compared to placebo at both primary and secondary endpoints. NOCITA was well-tolerated in that study as adverse reactions, such as discharge from the incision, incisional inflammation and vomiting, were infrequent and mild.
“There is a need to provide safe and effective analgesia during the post-perative period,” said Dr. Wofford. “Nocita leverages the efficacy of a local anesthetic with the added benefit of extended duration to provide up to 72 hours pain control following CCL stabilization surgery in dogs.”
Those attending ACVS were able to order NOCITA at the Aratana booth.
For a better understanding of how NOCITA works, watch the NOCITA Mechanism of Action video.
IMPORTANT SAFETY INFORMATION: NOCITA (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCI, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
The Company announced it submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM).
The Company announced its first quarter 2018 financial results. In the first quarter ended March 31, 2018, Aratana reported total net revenues of $4.0 million and a net loss of $8.5 million or $0.19 diluted loss per share.